Comparisons of AUCinf and Cmax between Phase 3 and phase 2b formulations, and planned commercial and Phase 2b formulations: 90% CI = 90% Confidence Interval; Ratio (Test/Reference); BE LL 90% CI = ...
The determination of topical bioequivalence requires a multi-faceted approach, tailored specifically to the generic-drug formulation. For a new generic-drug product to be approved by a regulatory ...
DUBLIN--(BUSINESS WIRE)--The "Bioanalytical Testing Services Market Size, Share & Trends Analysis Report By Molecule Type (Small Molecule, and Large Molecule), By Test Type (ADME, PK, PD, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback